Intermediate heparan sulfate binding during HPV-16 infection in HaCaTs

American Journal of Therapeutics

Volumn 21, Issue 5, 2014, Pages 331-342

  Kumar, Annandita ^a   Jacob, Taylor ^b   Abban, Cynthia Y ^a,c   Meneses, Patricio I ^b  

^a NEW YORK UNIVERSITY   (United States)

^b FORDHAM UNIVERSITY   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

HPV; HSPG binding; L1 C terminus

Indexed keywords

ALPHA6 INTEGRIN; ARGININE; HEPARAN SULFATE; HEPARANASE; L1 VIRUS PROTEIN; L2 VIRUS PROTEIN; LYSINE; SYNDECAN 1; UNCLASSIFIED DRUG; VIRUS PROTEIN; CAPSID PROTEIN; L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; SDC1 PROTEIN, HUMAN;

ADENOVIRUS INFECTION; AMINO ACID SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL MEMBRANE; CELL SURFACE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG BINDING; ENDOSOME; HUMAN; HUMAN ADENOVIRUS 5; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 6; PAPILLOMAVIRUS INFECTION; VIRUS CAPSID; VIRUS ENTRY; VIRUS INFECTION; VIRUS PARTICLE; VIRUS PURIFICATION; ADULT; CELL CULTURE; FEMALE; METABOLISM; PAPILLOMAVIRUS INFECTIONS; PHYSIOLOGY; UTERINE CERVICAL NEOPLASMS;

ADULT; CAPSID PROTEINS; CELLS, CULTURED; FEMALE; HEPARITIN SULFATE; HUMAN PAPILLOMAVIRUS 16; HUMANS; INTEGRIN ALPHA6; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; SYNDECAN-1; UTERINE CERVICAL NEOPLASMS;

EID: 84913586755     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0000000000000054     Document Type: Article

References (21)

1. Furumoto H, Irahara M. Human papilloma virus (HPV) and cervical cancer. J Med Invest. 2002;49:124-133.
2. Knipe DM, Howley P, eds. Fundamental Virology. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001: 1395.
3. Cutts FT, Franceshi S, Goldie S, et al. Human papilloma-virus and HPV vaccines: a review. Bull World Health Organ. 2007;85:719-726.
4. Surviladze Z, Dziduszko A, Ozbun MA. Essential roles for soluble virion-associated heparan sulfonated proteo-glycans and growth factors in human papillomavirus infections. PLoS Pathog. 2012;8:e1002519.
5. Lipovsky A, Popa A, Pimienta G, et al. Genome-wide siRNA screen identifies the retromer as a cellular entry factor for human papillomavirus. Proc Natl Acad Sci USA. 2013;110:7452-7457.
6. Buck CB, Cheng N, Thompson CD, et al. Arrangement of L2 within the papillomavirus capsid. J Virol. 2008;82: 5190-5197.
7. Modis Y, Trus BL, Harrison SC. Atomic model of the papillomavirus capsid. EMBO J. 2002;21:4754-4762.
8. Buck CB, Thompson CD, Pang YY, et al. Maturation of papillomavirus capsids. J Virol. 2005;79:2839-2846.
9. Schiller JT, Day PM, Kines RC. Current understanding of the mechanism of HPV infection. Gynecol Oncol. 2010;118 (1 Suppl):S12-S17.
10. Knappe M, Bodevin S, Selinka HC, et al. Surface-exposed amino acid residues of HPV16 L1 protein mediating interaction with cell surface heparan sulfate. J Biol Chem. 2007;282:27913-27922.
11. Lortat-Jacob H, Grosdidier A, Imberty A. Structural diversity of heparan sulfate binding domains in chemo-kines. Proc Natl Acad Sci USA. 2002;99:1229-1234.
12. Selinka HC, Giroglu T, Nowak T, et al. Further evidence that papillomavirus capsids exist in two distinct conformations. J Virol. 2003;77:12961-12967.
13. Cerqueira C, et al. Heparin increases the infectivity of human papillomavirus type 16 independent of cell surface proteoglycans and induces L1 epitope exposure. Cell Microbiol. 2013;15:1818-1836.
14. Buck CB, Pastrana DV, Lowy DR, et al. Efficient intra-cellular assembly of papillomaviral vectors. J Virol. 2004; 78:751-757.
15. Deschuyteneer M, Elouahabi A, Plainchamp D, et al. Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix, the AS04-adjuvanted HPV-16 and-18 cervical cancer vaccine. Hum Vaccin. 2010;6:407-419.
16. Dabydeen SA, Meneses PI. Smurf2 alters BPV1 trafficking and decreases infection. Arch Virol. 2011;156: 827-838.
17. Evander M, Frazer IH, Payne E, et al. Identification of the alpha6 integrin as a candidate receptor for papillomavi-ruses. J Virol. 1997;71:2449-2456.
18. Sun Jian, Ji-Sheng Y, Zhiwu Y, et al. The differences in heparin binding for the C-terminal basic-sequence-rich peptides of HPV-16 and HPV-18 capsid protein L1. J Chem Thermodynamics. 2012;47:130-137.
19. Richards KF, Bienkowska-Haba M, Dasgupta J, et al. Multiple heparan sulfate binding site engagements are required for the infectious entry of human papillomavi-rus type 16. J Virol. 2013;87:11426-11437.
20. Di Paolo NC, Kalyuzhniy O, Shayakhmetov DM. Fiber shaft-chimeric adenovirus vectors lacking the KKTK motif efficiently infect liver cells in vivo. J Virol. 2007; 81:12249-12259.
21. Nicklin SA, Wu E, Nemerow GR, et al. The influence of adenovirus fiber structure and function on vector development for gene therapy. Mol Ther. 2005;12:384-393.